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antihypertensive and endothelial modulating
activities
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Abstract
Background: Cardiovascular disorders (CVDs) are the leading cause of disease burden worldwide. Apart from
available synthetic drugs used in CVDs, there are many herbal formulations including POL-10 (containing 10 herbs),
which have been shown to be effective in animal studies but POL-10 was found to cause tachycardia in rodents as
its side effect. This study was designed to modify the composition of POL-10 for better efficacy and/or safety profile
in CVDs.
Methods: To assess the antidyslipidemic, antihypertensive and endothelial modulatory properties of two herbal
formulations, (ZPTO and ZTO) containing Z: Zingiber officinalis, P: Piper nigrum, T: Terminalia belerica and O: Orchis
mascula, different animal models including, tyloxapol and high fat diet-induced dyslipidemia and spontaneously
hypertensive rats (SHR) were used. Effect on endothelial function was studied using isolated tissue bath set up
coupled with PowerLab data acquisition system. The antioxidant activity was carried out using DPPH radical-
scavenging assay.
Results: Based on preliminary screening of the ingredients of POL-10 in tyloxapol-induced hyperlipidemic rats,
ZPTO and ZTO containing four active ingredients namely; Z, P, T and O were identified for further studies and com-
parison. In tyloxapol-induced hyperlipidemic rats, both ZPTO and ZTO caused significant reduction in serum trigly-
ceride (TG) and total cholesterol (TC). In high fat diet-fed rats, ZPTO decreased TC, low-density lipoproteins
cholesterol (LDL-C) and atherogenic index (AI). ZTO also showed similar effects to those of ZPTO with additional
merits being more effective in reducing AI, body weight and more importantly raising high-density lipoproteins. In
SHR, both formulations markedly reduced systolic blood pressure, AI and TG levels, ZTO being more potent in re-
versing endothelial dysfunction while was devoid of cardiac stimulatory effect. In addition, ZTO also reduced LDL-C
and improved glucose levels in SHR. In DPPH radical-scavenging activity test, ZTO was also more potent than ZPTO.
Conclusion: The modified formulation, ZTO was not only found more effective in correcting cardiovascular
abnormalities than ZPTO or POL-10 but also it was free from tachycardiac side-effect, which might be observed
because of the presence of Piper nigrum in ZPTO.
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Background
Cardiovascular diseases (CVDs) carry a major health
burden, affecting humankind [1]. Hypertension, dyslipid-
emia, endothelial dysfunction and oxidative stress are
the major pathologies involved in CVDs and impose a
great risk [2]. Apart from the synthetic drugs used for
controlling these pathologies, a number of traditional
herbal medicines have been in use in various cultures
around the world. A polyherbal formulation containing
10 herbs (POL-10), has been used in folk medicine of
Pakistan for cardiac ailments. In animal studies, POL-10
has been reported to possess antihypertensive, endothe-
lial modulating and antidyslipidemic activities in SHR
[3]. However, it caused an increase in the heart rate and
body weight in treated animals, which are considered
harmful side-effects in CVDs. This study was designed
to modify the composition of POL-10 for better efficacy
and/or safety profile for its use in CVDs. Based on pre-
liminary screening of the ingredients of POL-10 in
tyloxapol-induced hyperlipidemic rats, two formulations
containing four active ingredients namely; Z: Zingiber
officinalis (Ginger), P: Piper nigrum (Black pepper), T:
Terminalia belerica (Balela) and O: Orchis mascula
(Saalab misri), labeled as ZPTO and three ingredients
(excluding P), labeled as ZTO were identified for further
studies to compare their effect on high fat-diet induced
dyslipidemia, high blood pressure in spontaneous hyper-
tensive rats (SHR), body weight, endothelial function in
isolated vascular preparation of rats, and antioxidant ef-
fect using DPPH radical-scavenging assay.
It was also interesting to study the polyherbal formula-
tions as some of the ingredients of these selected formu-
lations, T. belerica [4,5]; Z. officianlis and P. nigrum [6]
have been reported to have synergistic activities when
used in combination with other medicinal herbs. Based
on a cultural belief in south Asia, the compound prepa-
rations are considered more effective and safer than the
single plant [7], which was supported by recent studies
on polyherbal formulations including trifala, in which, T.
belerica (also part of current study) is the essential in-
gredient [4].
The available data on the individual components of
selected polyherbal formulations; Z. officinalis [8,9], P.
nigrum [10,11], T. belerica [5,12] and O. mascula [13]
provide an indirect evidence for their effectiveness in
cardiovascular abnormalities using non-specific experi-
mental models. In addition, Z. officinalis [14,15] and O.
mascula [16] have also been studies individually in our
lab using a set of in-vitro assays and animal models for
their efficacy in cardiovascular disorders. However, there
is hardly any comprehensive study available indicating
the effectiveness of the selected combinations of medi-
cinal herbs in CVDs with synergistic and/or side effects
neutralizing potential, as the intake of single ingredient
alone at high dose for longer duration could be other-
wise harmful [17].
Methods
Plant material and extraction
All ingredients (Zingiber officinalis (Z), Piper nigrum (P),
Terminalia belerica (T), Orchis mascula (O) of ZPTO
were purchased from a local herbal store in Karachi,
Pakistan. The samples were authenticated by Mr. M.
Afzal Rizvi, a botanist at the Hamdard University,
Karachi. The individual samples were deposited in the
herbarium of Natural Products Research Division at the
Department of Biological and Biomedical Sciences, The
Aga Khan University, Karachi, Pakistan with respective
vouchers numbers assigned as ZO-RZ-03-06-75, PN-FT-
03-06-72, TB-FT-03-06-74 and OM-RT-03-06-70. The
components of ZPTO were ground to fine powder sep-
arately and finally mixed together in equal proportion
(50 g each). For chronic study, ZPTO and its slightly
modified form ZTO, which was prepared by excluding P
from ZPTO, in powdered form, were mixed in diet. For
free radical scavenging and acute toxicity tests, ZPTO
and ZTO were soaked in aqueous-methanol (30:70)
for three days with occasional shaking. It was filtered
through a muslin cloth and then through a Whatman
qualitative grade No.1 filter paper [18]. This procedure
was repeated three times and the filtrates were com-
bined and evaporated on rotary evaporator to obtain the
thick dark brown crude extract, yielding approximately
10% (wt/wt).
Drugs and standards
Acetylcholine chloride, cholesterol, cholic acid, phenyleph-
rine, potassium chloride and tyloxapol (triton WR-1339),
were obtained from the Sigma Chemical Company, St.
Louis, MO, U.S.A. Randox diagnostic kits for serum
analysis obtained from Randox Laboratories Ltd., Co.
Antrim, UK. All chemicals used were of the highest purity
grade. Physiological salt solutions were prepared fresh in
distilled water on the day of experiment, while stock solu-
tions of all the drugs and extract were made in distilled
water/saline and stored at −20°C and the dilutions were
prepared fresh on the day of the experiment.
Animals
Spontaneously Hypertensive Rats (Strain: SHR/NCrlBR;
hypertensive, non-stroke) and its normotensive controls
Wistar Kyoto Rats (WKY) were imported from Animal
Resource Centre, Australia at the age of 4 weeks. While
other animals such as, Sprague–Dawley (SD) rats (170–
200 g) and Balb/c mice (20–25 g) were sourced locally
and housed at the animal house of the Aga Khan
University. Animals were kept in their respective cages
with sawdust where needed (renewed after every 48 h),
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maintained at 23–25°C and had free access to food and
water. Experiments performed complied with the rul-
ings of the Institute of Laboratory Animal Resources,
Commission on Life Sciences, National Research
Council [19] and this study was part of the PhD pro-
posal of Dr. Nauman Aziz, approved by the Board of
Advanced Studies and Research, University of Karachi,
Karachi, Pakistan.
Preparation of diets
The diets (A-D) were prepared as;
A. Normal diet: The normal diet was prepared as
described previously by Harkness [20], at the animal
house of the Aga Khan University (AKU), Karachi.
The standard diet consisting of flour (5 Kg), chokar
(5 Kg), molasses (150 g), salt (75 g), nutrivet L
(33 g), potassium meta bisulphate (15 g), oil (500 g),
fish meal (2.25 Kg) and powdered milk (2 Kg) for a
total of about 13 Kg of the food material.
B. Treatment diets: ZPTO or ZTO (3% w/w) mixed in
diet A.
C. High fat/Atherogenic diet: Cholesterol (2% w/w),
cholic acid (0.5% w/w) and butter fat (5% w/w) were
added to A [21].
D. Treatment diet: ZPTO or ZTO (3% w/w) mixed in
diet C.
All measures were taken to ensure the uniform mixing
of additives and ZPTO or ZTO powder in dry ingredi-
ents of diet before kneading.
Pharmacological parameters
Study on tyloxapol-induced hyperlipidemia
An earlier described animal model of tyloxapol-induced
hyperlipidemia [22] was followed with slight modifica-
tions. Male Sprague–Dawley (SD) rats weighing 160–
180 g were randomly divided into 14 groups (6 in each),
group 1 and 2 were given diet A (normal diet) and group
3 and 4 were given diet B (normal diet with ZPTO or
ZTO), while animals in groups 5–8 were given normal
diet with Z, P, T or O. The remaining six groups were
administered remaining 6 components namely; Aristolo-
chia rotunda, Cinnamomum officinalis, Emblica officina-
lis, Matricaria chamomile, Piper longum and Plumbago
zeylanica, of original polyherbal formulation POL-10.
After 10 days of the treatment, all animals were fasted
for 7 h and group 1 received saline (10 ml/kg; i.p.), while
group 2–14 received tyloxapol (500 mg/kg; i.p.). On the
next day, the animals were anaesthetized by diethyl ether
and the blood was collected for analysis of serum total
cholesterol (TC) and triglycerides (TG) as described in
the section of “Estimation of lipid profile and glucose”.
Study on lipid profile, diet consumption and body weight
in high fat diet- fed rats
Both ZPTO and ZTO were studied for their effect on
high fat diet-induced hypercholesterolemia using a
method described by Berroughui et al. [23] with slight
modifications after pilot studies. The adult SD rats (12–
14 weeks old, weighing 140–160 g) were randomly di-
vided into 4 groups (7–10 animals in each group), group
1 was given diet A (served as normal control) and diet C
(atherogenic control) was administered to group 2, while
group 3 and 4 were given diet D (treated) for 8 weeks.
All animals had free access to water and diet. The diet
consumption was monitored daily and the change in
body weight was measured weekly for 8 weeks [23]. At
the end of 8th week of treatment, animals were fasted
16 h prior to blood collection and samples were ana-
lyzed for serum lipids and glucose as detailed in section
“Estimation of lipid profile and glucose”
Study on blood pressure, heart rate and lipid profile
in SHR
Male Spontaneously Hypertensive Rats (SHR) aged 20–
24 weeks, were randomly divided into 3 groups (n =7-8 in
each). Group 1 was given diet A (normal diet) and group 2
and 3 were given diet B (normal diet with ZPTO or ZTO)
for 8 weeks. Wistar Kyoto Rats (WKY) served as normo-
tensive control and given diet A for same period. The sys-
tolic blood pressure was estimated before start and during
8 weeks of the treatment by using a tail-cuff plethysmo-
graph (Model 92, IITC Inc., Woodland Hills, USA), coupled
to PowerLab 4/25 data acquisition system coupled to a
computer running Chart 5.3 software (ADInstruments,
Sydney, Australia). Heart rate was calculated online using
cyclic measurements option of the Chart software. Rats
were trained daily for ten days before starting the experi-
ment, in terms of the measurement of blood pressure. After
acclimatization with the blood pressure measurement pro-
cedure, 6–8 readings of systolic blood pressure of each con-
scious animal were recorded and median values calculated
after discarding maximum and minimum. The systolic
blood pressure was measured at 0, 4 and 8 weeks of the
treatment. The described non-invasive blood pressure
measurement is reported to have 96% correlation with dir-
ect blood pressure [24]. All animals had free access to water
and diet throughout study duration. At the end of 8th week
of treatment, the animals were fasted 16 h prior to blood
collection and samples were analyzed for serum lipids and
glucose as mentioned in section “Estimation of lipid profile
and glucose”
Study on vascular reactivity in rat aortae of SHR
At the end of the treatment, SHR and WKY were fasted
for 16 h, anaesthetized with diethyl ether by inhalation,
blood was collected via cardiac puncture and serum was
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analyzed for lipid profile and glucose. Thoracic aortae
were isolated and studied for endothelial reactivity. The
descending thoracic aortae were transferred immediately
to Kreb's buffer (composition in mmol/L: NaCl 118.4,
KCl 4.7, CaCl2 2.5, KH2PO4 1.2, MgSO4 1.2, NaHCO3
25, and glucose 11), cleaned of periadventitial tissue, and
were cut transversally into ring segments (3 mm in
length). Each ring was placed in a tissue bath filled with
Kreb's buffer (37°C) bubbled with carbogen (95% O2 and
5% CO2), and attached to a force transducer (model
FORT100) coupled to a Trans-bridge (model TBM4M,
World Precision Instruments, Hertfordshire, UK) and
PowerLab data acquisition system for measurement of
the isometric tension. Aortic rings were allowed to
equilibrate at least for 60 min at a resting tension of 2 g
with changes of buffer every 15 min. When the isometric
tension had stabilized, inhibitory concentration-response
curves (CRCs) of acetylcholine (ACh) 1 × 10-9 -10-5 mol/L
were constructed against contractions induced with sub-
maximal dose of phenylephrine (1 × 10-6 mol/L; PE) [25].
Estimation of lipid profile and glucose
The blood was collected in vacuutainer by cardiac puncture
from anaesthetized rats fasted overnight. The serum was
separated after centrifugation at 3000 rpm for 10 min. The
serum lipids and glucose were assayed enzymatically
using commercially available kits of Randox Laboratories,
Serum total cholesterol (TC), high-density lipoproteins
(HDL-C), triglyceride (TG) and glucose were deter-
mined by methods described by manufacture (Randox
Laboratories Ltd., Co. Antrim, UK). Low-density lipo-
proteins cholesterol (LDL-C) was estimated indirectly
by using formula: LDL = Total Cholesterol – HDL –
TG/5). Atherogenic index was calculated using for-
mula: Atherogenic index = TC-HDL/HDL) [26].
Free radical scavenging activity
With slight modifications in an earlier method of Misbah
et al. [27], a 0.1 mM solution of 1,1-diphenyl-2-picryl-
hydrazil (DPPH) radical in methanol was prepared and
1 ml of this solution was added to 3 ml of the extract solu-
tion in methanol at different concentrations and then ab-
sorbance was measured after 30 min at 517 nm. Decrease
in the absorbance of DPPH solution indicates an increase
in DPPH radical-scavenging activity. The percent DPPH
radical-scavenging activity was calculated by equation:
% DPPH radical scavenging
¼ 1−Control Absarbance−Sample Absorbance
Control Absorbance
 
 100
The DPPH solution was taken as the control. The
CRCs were plotted as the concentrations of extracts in
μg/ml against percent of free radical scavenging activity
for the calculation of median effective concentrations
(EC50) values along with 95% confidence interval.
Acute toxicity test
BALB/c mice were divided into 4 groups of 5 in each
and given increasing doses of the crude extracts of
ZPTO and ZTO (1, 2 and 3 g/kg) in a volume of 10 ml/
kg. A negative control group of mice was administered
saline (10 ml/kg, p.o.). Animals had free access to food
and water and kept under observation for 24 h for mor-
tality assessment [28].
Statistical analysis
All the data expressed as mean ± SEM and the EC50
values are presented as geometric mean with 95% confi-
dence intervals (CI). For comparison between means of
two groups unpaired Student’s t-test was used, while
One-way Analysis of Variance (One-way ANOVA) was
used to compare the differences in means of more than
two groups with control, followed by Dunnett’s multiple
comparison test. The concentration-response curves
(CRCs) were analyzed by using non-linear regression
analysis. Two-way ANOVA followed by Bonferroni’s
post-test correction was used for multiple comparisons
of CRCs with the respective control. P-values less than
0.05 (p < 0.05) were considered as statistically significant.
All the graphs, calculation and statistical analyses were
performed using GraphPad Prism software version 4.00
for Windows, (GraphPad Software, San Diego California
USA, www.graphpad.com).
Results
Effects of ZPTO, ZTO and their components on tyloxapol-
induced hyperlipidemia
In an attempt to compose a new formulation with better
efficacy and/or safety profile, individual ingredients of
POL-10, a previously studied polyherbal formulation [3],
were screened in this model. Administration of tyloxapol
to rats caused an increase in serum triglycerides (TG) to
6295 ± 499.30 vs. 71.56 ± 2.69 mg/dl (p < 0.001; n = 8-10)
and total cholesterol (TC) to 531.6 ± 30.01 vs. 89.51 ±
2.31 mg/dl (p < 0.001; n = 8-10) as compared to un-
treated animals. Out of 10 ingredients of POL-10, only 4
showed positive effect on serum TG and TC levels, while
remaining 6 components were found inactive in this
model (data not shown). Pretreatment of animals with
individual plants of the newly designed formulation
ZPTO caused a significant (p < 0.01) reduction in TG
with respective values of 3075 ± 119 mg/dL (Z. officina-
lis), 3536 ± 897.2 mg/dL (P. nigrum), 3588 ± 150.7 mg/dL
(T. belerica) and 2823 ± 114 mg/dL (O. mascula) com-
pared to 6295 ± 499.30 mg/dL (tyloxapol-administered
control). Similarly, both formulations ZPTO (2336 ±
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574 mg/dL) and ZTO (2499 ± 633.6 mg/dL) also pro-
duced a marked (p < 0.01) reduction on serum TG levels
compared to tyloxapol administered control. Both ZPTO
and ZTO were found more effective (at the 1/4th and 1/
3rd doses) in reducing TG when compared to the indi-
vidual ingredients.
In tyloxapol-induced hypercholesterolemia, pretreatment
of the animals with Z. officinalis (295.4 ± 99.92 mg/dL), O.
mascula (277.6 ± 84.74 mg/dL), P. nigrum (373 ± 66.09 mg/
dL), ZPTO (319.3 ± 61.29 mg/dL) and ZTO (341.9 ±
70.91 mg/dL) significantly (p < 0.01) prevented tyloxapol-
induced increase in TC levels. However, T. belerica (466.6
± 23.69 mg/dL) was found devoid of any effect (p > 0.05) on
TC levels. Both ZPTO and ZTO showed similar degree of
reduction in TC levels compared to their individual compo-
nents but at 1/4th and 1/3rd of the doses.
Effects of ZPTO and ZTO on lipid profile, diet
consumption and body weight in high fat diet- fed rats
An atherogenic diet fed for 8 weeks, caused a significant
increase in TC, LDL-C, atherogenic index and glucose
levels along with an increase in body weight of SD rats
compared to the data obtained from animals on normal
diet. Supplementation of 3% ZPTO and 3% ZTO to
atherogenic diet fed rats, caused a significant (p < 0.001)
reduction in TC, LDL-C, atherogenic index and daily
diet consumption. However, treatment with ZTO offered
additional benefits in terms of raising HDL-C. ZTO
showed comparatively better (p < 0.05) effect on athero-
genic index than ZPTO, while ZPTO caused stronger ef-
fect (p < 0.5) on glucose levels.
When studied for their effect on weight gain in obese rats
fed on atherogenic diet, ZPTO had no effect, however, a
marked reduction (p < 0.01) was observed in the body
weight of animals treated with ZTO. Both, ZPTO and ZTO
did not show any effect on TG levels (Table 1).
Effects of ZPTO and ZTO on blood pressure and lipid
profile in SHR
Treatment of SHR with 3% ZPTO or 3% ZTO for
8 weeks significantly reduced systolic blood pressure as
compared to untreated hypertensive control. Treatment
with ZPTO and ZTO significantly (p < 0.01) lowered sys-
tolic blood pressure in SHR. Treatment of animals with
ZPTO also increased (p < 0.001) heart rate in SHR, while
ZTO did not (p > 0.05) alter it. No change in HDL-C
levels was noticed in serum samples of animals treated
with ZPTO or ZTO, while a significant (p < 0.05) re-
duction was observed in LDL-C levels of animals
treated only with ZTO. Both preparations produced a
significant reduction in TG levels (p < 0.001) and
atherogenic indices (p < 0.01) when compared with
SHR control. On glucose levels, treatment of ZPTO
did not (p > 0.05) produce any effect, while ZTO ad-
ministration significantly (p < 0.01) improved glucose
levels in SHR when compared with untreated SHR as
shown in Table 2.
Effect of ZPTO and ZTO on vascular reactivity in isolated
rat aortae of SHR
Treatment of animals with 3% ZPTO or 3% ZTO for
8 weeks improved the acetylcholine (ACh)-mediated
endothelial-dependent relaxation of PE-induced con-
tractions in isolated aortae compared with those of
untreated controls. The comparative CRCs of ACh-
mediated endothelial-dependent relaxation in the
aortae of different groups of animals are presented in
Figure 1. The aortic tissues of animals treated with
ZTO produced greater relaxant response to ACh
application with an EC50 value of 0.06 μM (0.03-0.07,
n = 7-10) as compared to ZPTO [0.25 μM (0.10-0.29,
n = 7-10)], indicating a stronger effect of ZTO on vas-
cular reactivity (Figure 1).
Table 1 Effects of polyherbal formulations (ZPTO and ZTO) on serum lipids and glucose levels in atherogenic diet-fed
Sprague Dawley rats
Parameters ND AD AD + 3% ZPTO AD + 3% ZTO
Total Cholesterol (mg/dl) 74.62 ± 3.9 390.5 ± 3.09 ### 110.3 ± 12.14*** 110.7 ± 10.24***
HDL-C (mg/dl) 38.54 ± 1.7 27.82 ± 2.97 30.91 ± 3.1 82.6 ± 11.45***
LDL-C (mg/dl) 24.9 ± 2.8 304 ± 35.7 ### 74.5 ± 9.4*** 57.24 ± 10.8***
Triglycerides (mg/dl) 59.7 ± 4.2 65.2 ± 6.4 71.6 ± 11.6 49.5 ± 11.8
Atherogenic Index 0.92 ± 0.12 16.96 ± 3.15### 3.53 ± 0.813** 0.7 ± 0.155***
Glucose (mg/dl) 95.6 ± 7.2 147.5 ± 4.8 ### 94.18 ± 6.96*** 130.3 ± 3.15**
Daily diet consumption (g/Kg/day) 186.5 ± 11.8 161.8 ± 12.4# 78.9 ± 10.8*** 121.9 ± 7.1***
% Change in body weight 33.33 ± 1.6 56.8 ± 1.97### 53.2 ± 0.8 46.51 ± 1.61**
Normal Diet (ND) administered Sprague Dawley rats (SD), Atherogenic Diet (AD) administered SD rats; Polyherbal formulations, ZTO and ZPTO are composed of
Zingiber officinalis (Z), Terminalia belerica (T), Orchis mascula, or/and Piper nigrum (P); Values shown are Mean ± S.E.M. of 7–10 determinations.
#p <0.05 and ###p <0.001 compared to ND (Student t-test).
**p <0.01 and ***p <0.001 compared to AD (One-way ANOVA followed by Dunnett’s multiple comparison-test).
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Antioxidant activity
The crude methanolic extracts of ZPTO and ZTO were
studied for their antioxidant activity in DPPH free rad-
ical scavenging assay. Both formulations showed a sig-
nificant effect with EC50 values (95% CI; n = 3-6) and R
2
(a square of correlation coefficient, its value close to 1
shows better correlation between concentration and ac-
tivity and is also expressed as goodness of concentration
curve fitting) as ZPTO: 11.44 μg/mL (6.53-20.04; n = 3-
6, 0.991) and ZTO: 4.33 μg/mL (3.98-4.71; n = 3-6,
0.996). These effects were found similar to that of butyl
hydroxytoluene (BHT), used as a positive control, which
exhibited antioxidant effect with an EC50 value of
2.11 μg/mL (1.97-2.26; n = 3-6, 0.999). It is evident that
ZTO is almost three times more potent than ZPTO.
Acute toxicity test
In acute toxicity studies on mice, ZPTO and ZTO up to
3 g/kg per oral (p.o.) did not produce mortality in 48 h.
During chronic treatment for 6–8 weeks, ZPTO caused
increased in heart rate of SHR, while ZTO was devoid of
this effect. Both ZPTO and ZTO did not cause any
death or behavioral changes in normotensive rats and
SHR.
Discussion
A polyherbal formulation (POL-10) reported to exhibit a
side-effect, increasing heart rate and body weight in
treated animals [3]. The purpose of this study was to
modify the composition with better efficacy and/or
safety profile for its use in CVDs. Hyperlipidemia is the
major risk factor of CVDs. Tyloxapol-induced hyperlip-
idemia model is widely used for screening and exploring
mechanism of action of lipid lowering drugs. In this
assay, out of 10 ingredients of POL-10, only four
Zingiber officinalis, Piper nigrum, Terminalia belerica
and Orchis mascula were found active. Therefore, a
combination of all four ingredients (ZPTO) was studied
in further detail. Furthermore, P. nigrum also showed
some adverse effects like increase in atherognic index
and triglyceride levels in SHR. A second combination,
ZTO (without P. nigrum) was included in the study as
the improved version.
In normotensive SD rats, administration of tyloxapol
to rats at the dose of 500 mg/kg is known to cause dras-
tic increase in serum TG and TC levels due to enhanced
hepatic cholesterol synthesis particularly by increase in
HMG Co-A activity [29] and by the inhibition of lipo-
protein lipase responsible for hydrolysis of plasma lipids
[30]. In this model of hyperlipidemia, both ZPTO and
ZTO showed a significant reduction in TG and TC
levels with better efficacy than the parent formulation,
POL-10 [3]. Similarly, they were more effective (1/4th to
1/3rd of the dose) in reducing TG levels when compared
with its individual ingredients, indicating synergistic ef-
fect of these formulations on TG levels. These results
also showed that the new formulations possess lipid-
lowering effects possibly involving inhibition of lipid
biosynthesis.
High fat/atherogenic diet containing high cholesterol
and cholic acid induces endothelial dysfunction, athero-
sclerosis [31] and increases oxidative stress by increasing
the expression of oxidation-sensitive genes such as Elk-1
and p-CREB [32]. It is also known that high cholesterol
diet containing cholic acid increases TC, LDL-C, athero-
genic index and decreases HDL-C by enhancing intes-
tinal absorption and secretion and decreasing catabolism
of cholesterol [33]. Treatment of rats with ZTO or
ZPTO decreased serum TC and LDL-C levels, while no
change was observed on TG levels. ZTO was found su-
perior to ZPTO in terms of raising HDL-C. Similarly,
ZTO showed better efficacy in reducing atherogenic
index, while ZPTO was more effective only in reducing
glucose levels, which needs further studies. Considering
weight gain and increase in diet consumption leading to
obesity, a characteristic feature of high fat diets intake
Table 2 Effects of polyherbal formulations (ZPTO and ZTO), on blood pressure, serum lipids and glucose levels in SHR
Parameters WKY SHR SHR + 3% ZPTO SHR + 3% ZTO
Systolic BP (mmHg) 141.7 ± 2.4 200.9 ± 10.4### 174.4 ± 4.49** 173.3 ± 5.4**
Heart Rate (BPM) 312.0 ± 22.2 342.9 ± 6.1# 383 ± 18.9*** 349.1 ± 23.9
Total Cholesterol (mg/dl) 117.3 ± 5.1 93.3 ± 8.1# 76.8 ± 11.2 82.83 ± 5.3
HDL-C (mg/dl) 98.28 ± 5.8 70.15 ± 7.7## 66.5 ± 8.3 71.14 ± 4.5
LDL-C (mg/dl) 19.1 ± 3.4 23.13 ± 3.8 18.4 ± 3.6 12.3 ± 3*
Triglycerides (mg/dl) 82.85 ± 3.7 98.0 ± 4.4# 60.5 ± 5.3*** 64.2 ± 6.7***
Atherogenic Index 0.20 ± 0.04 0.37 ± 0.09### 0.15 ± 0.04** 0.17 ± 0.03**
Glucose (mg/dl) 113.4 ± 6.1 88 ± 13.6# 80.8 ± 7.8 130.3 ± 17.6**
Wistar Kyoto Rats (WKY), Spontaneously Hypertensive Rats (SHR).
Polyherbal formulations, ZTO and ZPTO are composed of Zingiber officinalis (Z), Terminalia belerica (T), Orchis mascula or/and Piper nigrum (P).
Values shown are Mean ± S.E.M. of 7–8 determinations.
#p <0.05; ##p <0.01; ###p <0.001 compared to WKY (Student t-test).
*p <0.05; **p <0.01; ***p <0.001 compared to SHR (One-way ANOVA followed by Dunnett’s multiple comparison-test).
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[34], both formulations were also compared for their ef-
fect on diet consumption and weight gain. ZPTO was
found more effective (P < 0.01) in reducing diet con-
sumption, while only ZTO reduced the weight gain of
obese rats on atherogenic diet, showing its additional
weight reducing potential, which was not seen in case of
ZPTO. These data clearly indicate that in atherogenic
diet-fed animal model, ZTO is more beneficial than
ZPTO or POL-10 [3]. ZTO also caused reduction in
atherogenic index, and raised HDL-C, which are consid-
ered better indicators of coronary heart disease risk than
individual lipoprotein concentration [35], thus showing
additional merit, particularly when lipid lowering chem-
ical drugs have limited success in correcting HDL-C
abnormality [36]. SHR model is the most widely used
animal model to equate with human essential hyperten-
sion, due to its similarities in genetic predisposition to
high blood pressure without specific etiology, increased
total peripheral resistance without volume expansion,
impairment of endothelial function and similar re-
sponses to the drug treatments [37]. Vascular endothe-
lium plays an important role in regulation of blood
pressure through the synthesis and secretion of a variety
of vasoactive substances. In SHR, vascular endothelial
dysfunction is caused by a variety of factors, such as
hypertension [38], hypertriglyceridemia [39] and excess
production of oxidants and/or deficiency of antioxidant
systems [40]. Treatment of SHR with ZPTO or ZTO re-
duced systolic blood pressure, TG and atherogenic index
with comparable efficacy, whereas, ZTO was more ef-
fective than ZPTO in improving endothelial dysfunction.
A major limitation of ZPTO was its ability to increase
heart rate in SHR, while ZTO was devoid of this harmful
effect. Unlike ZPTO, it also reduced LDL-C and im-
proved hyperglycemia, indicating additional merit of
ZTO over ZPTO or POL-10 [3].
High fat diet is known to cause oxidative stress (en-
zymatic and non-enzymatic) in rats, indicated by ele-
vated levels of thiobarbituric acid reactive substances,
conjugated dienes and significantly lowered activities of
superoxide dismutase, catalase, glutathione peroxidase,
glutathione-S-transferase and reduced glutathione in the
liver, heart, kidney, intestine and aorta. Antioxidants
effectively prevent such kind of cellular damages [41].
Interestingly, when tested in DPPH assay, ZPTO and
ZTO exhibited strong antioxidant activity, which may
offer additional benefit in combating the oxidative stress
caused by high cholesterol. In SHR, oxidative stress
causes disturbance in calcium homeostasis, which is es-
sential for the synthesis and release of nitric oxide (NO)
from endothelial cells [42]. Antioxidant properties of
new formulations may have played a role in improving
NO release and synthesis as indirectly observed in their
endothelial modulating potentials. ZTO was found more
effective than ZPTO in its antioxidant effect, suggesting
another merit of ZTO over ZPTO.
In earlier study, POL-10 was reported to increase heart
rate in SHR [3], as was observed with ZPTO but not
with ZTO in this study. Piper nigrum is the only
Figure 1 Dose–response curves showing the vasorelaxant
effects of acetylcholine on phenylephrine-induced (PE: 1 μM)
vasoconstriction in aortae isolated from Spontaneously hyper-
tensive rats (SHR) and Wistar Kyoto rats (WKY) and SHR treated
with 3% ZTO (A) and ZPTO (B) for the period of two months.
Curves represent mean ± S.E.M of responses from 5–10 animals. (#p
<0.05, ###p <0.001 showing comparison of WKY with SHR, student
t-test *p <0.05, ***p <0.001 showing comparison of SHR + 3% ZTO or
ZPTO with SHR; Two-way ANOVA, Bonferroni post-test).
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component, which is making ZTO different from ZPTO
and was also a constituent of POL-10. P. nigrum and its
main alkaloid constituent, piperine have been reported
to possess monoamine oxidase inhibitory (MAOI) activ-
ity [43]. MAOIs are known to cause inhibition of oxida-
tive deamination of monoamines such as, serotonin,
dopamine and norepinephrine and eventually increase
their half-lives and activities. Increased levels of norepin-
ephrine, might be responsible for increase in heart rate
caused by ZPTO in SHR, though other mechanism(s)
cannot be ruled out.
Taking together, the important differences in athero-
genic diet-fed rat model were; ZTO was more effective
in correcting atherogenic index and HDL-C than ZPTO.
Similarly in SHR model, ZTO and ZPTO were found
equally effective and relatively more efficacious (p < 0.05)
in their antihypertensive action than POL-10 [3], while
ZTO was more effective for its positive impact on
endothelial vascular reactivity and was also free from
tachycardiac side effect, when compared with ZPTO or
POL-10 [3]. Moreover, ZTO reduced LDL-C and glu-
cose levels, but not shared by ZPTO. The cumulative
better effective profile of ZTO in CVDs might be
because of the individual beneficial effects of its com-
ponents; Z. officinalis [14,15,44], T. belerica [45,46]
and O. mascula [16].
The use of polyherbal formulations compared to indi-
vidual herbs are not only encouraged culturally in the
Indo-Pak sub-continent [17], but also supported by evi-
dence possessing the synergistic interactions, thus offer-
ing intake of the individual ingredients at lower doses
for longer duration, which could otherwise be harmful.
Moreover, the selected ingredients of ZPTO and ZTO
are known for their synergistic therapeutic action when
used with other medicinal herbs in combinations such
as, Trifla containing T. belerica as one of its component,
which is a popular herbal formulation for its effective-
ness in hypercholesterolemia [4] compared to the indi-
vidual hypolipidemic potential of T. belerica [5].
Similarly, Trikatu, a polyherbal formulation corrects de-
ranged lipid in a better way [6] compared to the individ-
ual effectiveness of Z. officinalis [8,9] and P. nigrum
[10,11]. The present study also proves better efficacy and
safety of O. mascula in the form of mixture compared to
its individual actions [16].
Conclusion
These findings suggest that the modified formulation
containing: Zingiber officinalis, Terminalia belerica and
Orchis mascula was relatively more effective as antidysli-
pidemic, antihypertensive, antioxidant and endothelial
modulating agent, as well as offers better safety profile
compared to its parent formulations ZPTO or POL-10.
However, further detailed studies on phytochemical,
toxicological and pharmacological aspects are required
on ZTO, before making it available for clinical trials.
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